Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
Introduction Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is moderate, and relapse rates are high. Preliminary findings suggest that psilocybin, a psychedelic compound, can safely and reliably occasion highly meani...
Saved in:
| Main Authors: | Claus Thorn Ekstrøm, Patrick MacDonald Fisher, Gitte Moos Knudsen, Dea Siggaard Stenbæk, Anders Fink-Jensen, Mathias Ebbesen Jensen, Tobias Søgaard Juul |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-10-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/10/e066019.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience
by: Hanna M. Tolle, et al.
Published: (2024-02-01) -
No evidence for a role of the serotonin 4 receptor in five-factor personality traits: A positron emission tomography brain study.
by: Dea Siggaard Stenbæk, et al.
Published: (2017-01-01) -
Computational modelling and neural correlates of reinforcement learning following three-week escitalopram: a double-blind, placebo-controlled semi-randomised study
by: Christelle Langley, et al.
Published: (2025-05-01) -
Psilocybin’s acute and persistent brain effects: a precision imaging drug trial
by: Subha Subramanian, et al.
Published: (2025-06-01) -
Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials
by: Francesco Bevione, et al.
Published: (2025-07-01)